

Please type a plus sign (+) inside this box → ☐

3 (Modified) PTO/SB/21 (4-98)
Approved for use through 09/30/2000. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.



TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission	Application Number	09/896,896
	Filing Date	June 29, 2001
	First Named Inventor	Jens Okkels
	Group Art Unit	1633
	Examiner Name	Unassigned
Attorney Docket Number		31-001700US

TECH CENTER 1600/2900
OCT 11 2001

RECEIVED


ENCLOSURES (check all that apply)		
<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Assignment Papers (for an Application)	<input type="checkbox"/> After Allowance Communication to Group
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment / Response	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition Routing Slip (PTO/SB/69) and Accompanying Petition	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input checked="" type="checkbox"/> Additional Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	1449 PTO-Form and Receipt acknowledgment postcard
<input checked="" type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Small Entity Statement	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> Request for Refund	
<input type="checkbox"/> Response to Missing Parts/Incomplete Application	Authorization to Charge Deposit Account Please charge Deposit Account No. 50-0893 for any additional fees associated with this paper or during the pendency of this application, including any extensions of time for consideration of the documents enclosed.	
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	Remarks	

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual name	Jonathan Alan Quine Reg. No. 41,261 The Law Offices of Jonathan Alan Quine		
Signature			
Date	October 5, 2001		

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on this date: October 5, 2001			
Typed or printed name	Evelyn Gomez		
Signature		Date	October 5, 2001



I hereby certify that the enclosed correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231,
On October 5, 2001

The Law Offices of Jonathan Alan Quine

By Evelyn Gomez
Evelyn Gomez

RECEIVED

OCT 11 2001

TECH CENTER 1600/2900

Attorney Docket No. 31-001700US
Client Ref. No. 0217us210

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Jens Okkels, *et al.*

Application No.: 09/896,896

Filed: June 29, 2001

For: PEPTIDE EXTENDED
GLYCOSYLATED POLYPEPTIDES

Examiner: Unassigned

Art Unit: 1633

INFORMATION DISCLOSURE
STATEMENT UNDER 37 CFR § 1.97 and
§ 1.98

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

The references cited on attached form PTO-1449 are being called to the attention of the Examiner. Copies of the references are enclosed. It is respectfully requested that the cited information be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

Applicant believes that no fee is required for submission of this statement, since it is being submitted prior to the first Office Action. However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 50-0893. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,

A handwritten signature in black ink, appearing to read "Jonathan Alan Quine", with a stylized flourish at the end.

Jonathan Alan Quine
Reg. No. 41,261

THE LAW OFFICES OF JONATHAN ALAN QUINE
P.O. Box 458
Alameda, CA 94501
Tel: (510) 337-7871
Fax: (510) 337-7877

JAQ: emg



Substitute for form 1449A-B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Complete if Known	
	Application Number	09/896,896
	Filing Date	June 29, 2001
	First Named Inventor	Jens Okkels
	Group Art Unit	1633
	Examiner Name	Unassigned
	Attorney Docket Number	31-001700US

RECEIVED

OCT 11 2001

TECH CENTER 1600/2900

U.S. PATENT DOCUMENTS						
Examiner Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, lines, Where Relevant Passages or Relevant Figures Appeal
		Number	Kind Code (if known)			
	AA	5,041,376		Gething et al.	08-20-1991	
	AB	5,218,092		Sasaki et al.	06-08-1993	
	AC	5,338,835		Boime	08-16-1994	
	AD	5,508,261		Moyle et al.	04-16-1996	

FOREIGN PATENT DOCUMENTS								
Examiner Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Office	Number	Kind Code (if known)				
	AE	WO	95/05465	A1	Amgen, Inc.	02-23-1995		
	AF	WO	97/04079	A1	Novo Nordisk A/S	02-06-1997		
	AG	WO	97/30161	A1	Applied Research Systems ARS Holding N.V.	08-21-1997		
	AH	WO	00/26354	A1	Novo Nordisk A/S	05-11-2000		

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T	
	AI	Guan et al., Cell, 1985 Vol. 42, 489-496		
	AJ	Machamer et al. J. Biol. Chem., 1998, 263, 5948-5954		
	AK	Machamer et al. J. Biol. Chem., 1998, 263, 5955-5960		
	AL	Matsuura et al., Nature Biotechnology, 1999, Vol. 17, 58-61		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.